Recently, it was shown in a small cohort of 30 patients with systolic heart failure and acute decompensation; the administration of IL-1 blocker, anakinra reduced the inflammatory burden as shown by reduced C-reactive protein levels within 72 h. Here, IL1B is linked to systolic heart failure.